<scp>ISPAD</scp>
            Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents

Besser, Rachel; Bell, Kirstine J.; Couper, Jennifer; Ziegler, Anette‐G.; Wherrett, Diane K.; Knip, Mikael; Speake, Cate; Casteels, Kristina; Driscoll, Kimberly A.; Jacobsen, Laura M.; Craig, Maria E.

doi:10.1111/pedi.13410

Cited by 73 publications

(84 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Prävention Und Behandlung Des Typ-1-diabetes Im Frühstadiumunclassified

“…Inzwischen sind aber selektive Immuntherapeutika mit besserem Verträglichkeitsprofil verfügbar, die auch bei kurzzeitigem Einsatz direkt nach klinischer Manifestation die C-Peptid-Abnahme verlangsamen. Kinder und Jugendliche hatten in den klinischen Studien meist ein deutlich besseres Ansprechen als Erwachsene 17 , 21 .…”

Section: Prävention Und Behandlung Des Typ-1-diabetes Im Frühstadiumunclassified

“…B. Coxsackie-B-Viren) sich möglicherweise schützend auswirken. Die Induk tion einer Immunregulation durch Beeinflussung des Mikrobioms ist ein weiterer aktuell verfolgter Ansatz[7,16,17].In der SINT1A-Studie wird aktuell überprüft, ob bei Säuglingen mit erhöhtem T1D-Risiko durch die Verabreichung des Probiotikums B. infantis die Entstehung der Autoimmunität verhindert werden kann. Das Probiotikum soll einen positiven Einfluss auf die Darmflora haben und dadurch regulierend auf das Immunsystem wirken (Informationen unter www.gppad.org/de/praevention; Stand: 08.02.2023).…”

unclassified

See 2 more Smart Citations

Früherkennung und Prävention des Typ-1-Diabetes

2023

View full text Add to dashboard Cite

ZUSAMMENFASSUNGTechnologischer Fortschritt und das Verständnis der zugrunde liegenden Immunpathogenese der Erkrankung Diabetes mellitus Typ 1 (T1D) haben zu Veränderungen in den präventiven und therapeutischen Ansätzen geführt. Diese zielen darauf ab, das Entstehen des Autoimmunprozesses zu verhindern oder dessen Voranschreiten zumindest zu verlangsamen bzw. die Zerstörung von Betazellen aufzuhalten oder hinauszuzögern. Die Zulassung erster Medikamente für den Einsatz bei Kindern und Jugendlichen im fortgeschrittenen Frühstadium oder kurz nach klinischer Manifestation ist bereits in Aussicht 1.

show abstract

Section: Prävention Und Behandlung Des Typ-1-diabetes Im Frühstadiumunclassified

unclassified

See 1 more Smart Citation

Früherkennung und Prävention des Typ-1-Diabetes

2023

View full text Add to dashboard Cite

show abstract

“…While individuals with a first‐degree relative with T1D have ~15‐fold increased risk of T1D, approximately 85% of those with a new diagnosis do not have a family history of T1D. Hence, general population screening programs to determine T1D risk are expanding, and collaborative T1D networks testing interventions seeking to delay the disease process at all stages of disease are growing, including the use of CGM as a way to assess risk and track glycemia in these settings 3 …”

Section: Ada Evidence‐grading System For “Standards Of Medical Care I...mentioning

confidence: 99%

“…Moreover, in the 27 years since the first guidelines were published, 2 Hence, general population screening programs to determine T1D risk are expanding, and collaborative T1D networks testing interventions seeking to delay the disease process at all stages of disease are growing, including the use of CGM as a way to assess risk and track glycemia in these settings. 3 For type 2 diabetes (T2D), follow-up of large cohorts from around the globe continue to inform the rates of co-morbidities and complications in youth-onset T2D, while pharmacologic therapies for the treatment of youth-onset T2D have expanded. 4 For monogenic diabetes, technological advances include the use of next-generation sequencing, which is now considered the best approach for early molecular diagnosis and to guide treatment, particularly for neonatal diabetes.…”

mentioning

confidence: 99%

ISPAD Clinical Practice Consensus Guidelines 2022: Editorial

et al. 2022

Self Cite

View full text Add to dashboard Cite

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

Hendriks,

Marcovecchio,

Besser

et al. 2024

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

Background/AimType 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta‐cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As screening activity to identify autoantibody‐positive individuals increases, a rise in presymptomatic type 1 diabetes individuals seeking medical attention is expected. Current guidance on how to monitor these individuals in a safe but minimally invasive way is limited. This article aims to provide clinical guidance for monitoring individuals with presymptomatic type 1 diabetes to reduce the risk of diabetic ketoacidosis (DKA) at diagnosis.MethodsExpert consensus was obtained from members of the Fr1da, GPPAD, and INNODIA consortia, three European diabetes research groups. The guidance covers both specialist and primary care follow‐up strategies.ResultsThe guidance outlines recommended monitoring approaches based on age, disease stage and clinical setting. Individuals with presymptomatic type 1 diabetes are best followed up in specialist care. For stage 1, biannual assessments of random plasma glucose and HbA1c are suggested for children, while annual assessments are recommended for adolescents and adults. For stage 2, 3‐monthly clinic visits with additional home monitoring are advised. The value of repeat OGTT in stage 1 and the use of continuous glucose monitoring in stage 2 are discussed. Primary care is encouraged to monitor individuals who decline specialist care, following the guidance presented.ConclusionsAs type 1 diabetes screening programs become more prevalent, effective monitoring strategies are essential to mitigate the risk of complications such as DKA. This guidance serves as a valuable resource for clinicians, providing practical recommendations tailored to an individual's age and disease stage, both within specialist and primary care settings.

show abstract

ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents

Cited by 73 publications

References 136 publications

Früherkennung und Prävention des Typ-1-Diabetes

Früherkennung und Prävention des Typ-1-Diabetes

ISPAD Clinical Practice Consensus Guidelines 2022: Editorial

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

Contact Info

Product

Resources

About